2024
Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians
Wiseman A, Alhamad T, Alloway R, Concepcion B, Cooper M, Formica R, Klein C, Kumar V, Leca N, Shihab F, Taber D, Mulnick S, Bushnell D, Hadi M, Bunnapradist S. Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians. Annals Of Transplantation 2024, 29: e943498-1-e943498-13. PMID: 38526543, PMCID: PMC10944009, DOI: 10.12659/aot.943498.Peer-Reviewed Original ResearchMeSH KeywordsBlack or African AmericanClinical Decision-MakingDelphi TechniqueHumansKidney TransplantationTacrolimusConceptsLCP-tacrolimusImmediate-release tacrolimusKidney transplantationFirst-line optionKidney transplant recipientsRandomized clinical trialsDe novo settingTacrolimus formulationReview available dataEvidence-based recommendationsTrough levelsOnce-dailyTransplant recipientsClinical decision-makingOptimal doseClinical trialsExpert cliniciansConsensus statementTransplant expertsStrength of evidenceClinical practiceKidneyTacrolimusDe novoDelphi consensus survey
2023
Physician Preferences when Selecting Candidates for Lower-Quality Kidney Offers
Sepulveda J, Mehrotra S, Yang J, Schantz K, Becker Y, Formica R, Ladner D, Kaufman D, Friedewald J. Physician Preferences when Selecting Candidates for Lower-Quality Kidney Offers. Clinical Journal Of The American Society Of Nephrology 2023, 18: 1599-1609. PMID: 37729938, PMCID: PMC10723918, DOI: 10.2215/cjn.0000000000000302.Peer-Reviewed Original ResearchMeSH KeywordsDiabetes MellitusGraft SurvivalHumansKidneyKidney TransplantationPhysiciansTissue and Organ ProcurementTissue DonorsUnited StatesConceptsCold ischemia timePanel reactive antibodyIschemia timeMarginal kidneysEjection fractionReactive antibodiesRecipient characteristicsPost-transplant survival scoreSignificant associationKidney Donor Profile IndexKarnofsky performance scoreSerum creatinine levelsHistory of diabetesLow-quality kidneysHLA mismatchesPerformance statusRecipient ageCreatinine levelsDiabetes statusHLA matchCirculatory deathKidney qualityYounger recipientsDonor ageDiscrete choice experiment
2022
A Composite End Point of Graft Status and eGFR at 1 Year to Improve the Scientific Registry of Transplant Recipients’ Five-Tier Rating System
Wang K, Deng Y, Stewart D, Formica R. A Composite End Point of Graft Status and eGFR at 1 Year to Improve the Scientific Registry of Transplant Recipients’ Five-Tier Rating System. Journal Of The American Society Of Nephrology 2022, 33: 1613-1624. PMID: 35537779, PMCID: PMC9342646, DOI: 10.1681/asn.2022010078.Peer-Reviewed Original ResearchMeSH KeywordsGraft SurvivalHumansKidney TransplantationRegistriesTissue DonorsTransplant RecipientsTreatment OutcomeUnited StatesConceptsComposite end pointTraditional end pointsTransplant programsEnd pointAllograft functionGraft survivalScientific RegistryFive-tier systemLong-term graft outcomeDonor graft survivalKidney transplant programAllograft failureAllograft survivalGraft outcomeTransplant recipientsGraft statusGraft failureEGFR differenceSRTR dataSurvival rateEGFRSurvivalRegistryMeaningful differencesConcept study
2020
Physician and patient acceptance of policies to reduce kidney discard
Mehrotra S, Schantz K, Friedewald JJ, Ladner DP, Becker Y, Formica R, Barah M, Gu J, Gordon EJ. Physician and patient acceptance of policies to reduce kidney discard. Clinical Transplantation 2020, 34: e14054. PMID: 32738167, PMCID: PMC7929781, DOI: 10.1111/ctr.14054.Peer-Reviewed Original ResearchMeSH KeywordsDonor SelectionGraft SurvivalHumansKidneyKidney TransplantationPhysiciansPolicyRisk FactorsTissue and Organ ProcurementTissue DonorsUnited StatesConceptsDeceased donor kidneysMajority of physiciansDonor kidneysKidney allocation policyShortage of kidneysRisk of discardAggressive centersGraft failureSurvival benefitSuitable patientsTransplant physiciansPatient acceptancePatientsKidneyPhysiciansPatient organizationsProfessional societiesKDPITransplantationMajorityMonthsA call to action: Feasible strategies to reduce the discard of transplantable kidneys in the United States
Stewart ZA, Shah SA, Formica RN, Kandaswamy R, Paramesh AS, Friedman J, Squires R, Cooper M, Axelrod DA. A call to action: Feasible strategies to reduce the discard of transplantable kidneys in the United States. Clinical Transplantation 2020, 34: e13990. PMID: 32621660, DOI: 10.1111/ctr.13990.Peer-Reviewed Original ResearchMeSH KeywordsDonor SelectionHumansKidneyKidney TransplantationRetrospective StudiesRisk FactorsTissue and Organ ProcurementTissue DonorsUnited StatesConceptsOrgan utilizationHigh-kidney donor profile index kidneysAcceptable post-transplant outcomesLow-risk organPost-transplant outcomesCold ischemic timeCold ischemia timeDeceased donor kidneysKidney allocation systemHigher transplant ratesNew allocation policyOrgan acceptanceIschemic timeDonor kidneysIschemia timeTransplant ratesOrgan discardRisk organsPractice patternsTransplantable kidneysClinical practicePathological interpretationGeographic sharingKidneyFinancial barriersOutpatient Management of the Kidney Transplant Recipient during the SARS-CoV-2 Virus Pandemic
Gleeson SE, Formica RN, Marin EP. Outpatient Management of the Kidney Transplant Recipient during the SARS-CoV-2 Virus Pandemic. Clinical Journal Of The American Society Of Nephrology 2020, 15: cjn.04510420. PMID: 32345749, PMCID: PMC7274284, DOI: 10.2215/cjn.04510420.Peer-Reviewed Original ResearchThe Broader Sharing of Deceased Donor Kidneys Is an Ethical and Legal Imperative
Klarman SE, Formica RN. The Broader Sharing of Deceased Donor Kidneys Is an Ethical and Legal Imperative. Journal Of The American Society Of Nephrology 2020, 31: asn.2020020121. PMID: 32312798, PMCID: PMC7269362, DOI: 10.1681/asn.2020020121.Commentaries, Editorials and Letters
2019
Should the United States employ free market practices to solve the hidden public health crisis of chronic kidney disease?
Formica RN, Gill JS. Should the United States employ free market practices to solve the hidden public health crisis of chronic kidney disease? American Journal Of Transplantation 2019, 20: 1217-1218. PMID: 31746545, DOI: 10.1111/ajt.15718.Peer-Reviewed Original ResearchMeSH KeywordsHumansKidneyKidney TransplantationPublic HealthRenal Insufficiency, ChronicUnited StatesEconomic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era
Kadatz M, Gill JS, Gill J, Formica RN, Klarenbach S. Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era. Journal Of The American Society Of Nephrology 2019, 31: 218-228. PMID: 31704739, PMCID: PMC6934999, DOI: 10.1681/asn.2019070646.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsQuality-adjusted life yearsTransplant recipientsTransplant survivalDrug coverageMedicare coverageTransplant failureImmunosuppressant drugsAdditional quality-adjusted life yearCohort of MedicareMultivariable survival analysisIncremental cost-utility ratioBetter patient outcomesCost-utility ratioImmunosuppressant medicationsTransplant functionImmunosuppressive drugsPatient outcomesMedicare payersSurvival analysisLife yearsIncremental costRecipientsSurvivalDrugsSafety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant
Redfield RR, Jordan SC, Busque S, Vincenti F, Woodle ES, Desai N, Reed EF, Tremblay S, Zachary AA, Vo AA, Formica R, Schindler T, Tran H, Looney C, Jamois C, Green C, Morimoto A, Rajwanshi R, Schroeder A, Cascino MD, Brunetta P, Borie D. Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. American Journal Of Transplantation 2019, 19: 3035-3045. PMID: 31257724, PMCID: PMC6899639, DOI: 10.1111/ajt.15514.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibodies, Monoclonal, HumanizedAntigens, CD20Antineoplastic Agents, ImmunologicalCohort StudiesDesensitization, ImmunologicFemaleFollow-Up StudiesGraft SurvivalHLA AntigensHumansKidney Failure, ChronicKidney TransplantationMaleMaximum Tolerated DoseMiddle AgedPatient SelectionPrognosisRisk FactorsTissue DistributionYoung AdultConceptsB-cell depletionSerious adverse eventsIntravenous immunoglobulinCell depletionAdverse eventsOpen-label phase 1b studyType 2Doses of IVIGIncomplete B cell depletionPanel reactive antibody scorePeripheral B-cell depletionEnd-stage renal diseasePhase 1b studyAnti-HLA antibodiesRetroperitoneal lymph nodesSingle antigen beadsTime of transplantCD20 monoclonal antibodyMedian followRenal transplantKidney transplantMost patientsWeek 24Lymph nodesRenal diseaseESKD Risk in Living Kidney Donors “Like Me”
Newell KA, Formica RN. ESKD Risk in Living Kidney Donors “Like Me”. Clinical Journal Of The American Society Of Nephrology 2019, 14: 970-971. PMID: 31278113, PMCID: PMC6625628, DOI: 10.2215/cjn.06010519.Peer-Reviewed Original Research
2018
Report of National Kidney Foundation Consensus Conference to Decrease Kidney Discards
Cooper M, Formica R, Friedewald J, Hirose R, O’Connor K, Mohan S, Schold J, Axelrod D, Pastan S. Report of National Kidney Foundation Consensus Conference to Decrease Kidney Discards. Clinical Transplantation 2018, 33: e13419. PMID: 30345720, DOI: 10.1111/ctr.13419.Peer-Reviewed Original ResearchMeSH KeywordsConsensusDonor SelectionHumansKidney TransplantationPractice Guidelines as TopicTissue and Organ ProcurementTissue DonorsAnd equal access for all? The future of deceased donor kidney allocation
Formica RN. And equal access for all? The future of deceased donor kidney allocation. American Journal Of Transplantation 2018, 18: 1837-1838. PMID: 29878578, DOI: 10.1111/ajt.14964.Peer-Reviewed Original ResearchAnalysis of Biomarkers Within the Initial 2 Years Posttransplant and 5-Year Kidney Transplant Outcomes
Faddoul G, Nadkarni GN, Bridges ND, Goebel J, Hricik DE, Formica R, Menon MC, Morrison Y, Murphy B, Newell K, Nickerson P, Poggio ED, Rush D, Heeger PS. Analysis of Biomarkers Within the Initial 2 Years Posttransplant and 5-Year Kidney Transplant Outcomes. Transplantation 2018, 102: 673-680. PMID: 29189482, PMCID: PMC6018026, DOI: 10.1097/tp.0000000000002026.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkersChemokine CXCL9Enzyme-Linked Immunospot AssayFemaleGlomerular Filtration RateGraft RejectionGraft SurvivalHumansInterferon-gammaInterferon-gamma Release TestsKidneyKidney TransplantationMaleMiddle AgedNorth AmericaPredictive Value of TestsProspective StudiesRisk FactorsTime FactorsTreatment OutcomeConceptsEnzyme-linked immunosorbent spotGraft lossAcute cellular rejectionKidney allograft lossKidney transplant outcomesGlomerular filtration rateMultivariable logistic regressionAllograft lossCellular rejectionCXCL9 levelsUrinary CXCL9Year posttransplantTransplant outcomesImmunosorbent spotUnivariable analysisChemokine measurementsFiltration rateSurrogate markerClinical trialsLate outcomesOrgan transplantationT cellsInterferon gammaAnalysis of biomarkersLogistic regressionThe role of the kidney in combined liver‐kidney transplantation
Formica RN. The role of the kidney in combined liver‐kidney transplantation. Liver Transplantation 2018, 24: 164-165. PMID: 29222928, DOI: 10.1002/lt.24995.Peer-Reviewed Original Research
2017
Transition probabilities between changing sensitization levels, waitlist activity status and competing-risk kidney transplant outcomes using multi-state modeling
Kulkarni S, Hall I, Formica R, Thiessen C, Stewart D, Gan G, Greene E, Deng Y. Transition probabilities between changing sensitization levels, waitlist activity status and competing-risk kidney transplant outcomes using multi-state modeling. PLOS ONE 2017, 12: e0190277. PMID: 29287087, PMCID: PMC5747475, DOI: 10.1371/journal.pone.0190277.Peer-Reviewed Original ResearchConceptsTransplant probabilityTransplant outcomesActivity statusKidney transplant outcomesKAS implementationPost-KASWaitlist mortalityPatient characteristicsOPTN databaseMulti-state modelingStatistical differenceSensitization levelOutcomesTransplantCohortImpact outcomesCPRAStatus combinationsStatusMortalityWhitesSensitizationPerspectives on the Strengths and Weaknesses of the National Kidney Allocation System
Formica RN. Perspectives on the Strengths and Weaknesses of the National Kidney Allocation System. Clinical Journal Of The American Society Of Nephrology 2017, 12: 2056-2056. PMID: 29162591, PMCID: PMC5718280, DOI: 10.2215/cjn.08640817.Peer-Reviewed Original ResearchUtility of Applying Quality Assessment Tools for Kidneys With KDPI ≥80
Doshi MD, Reese PP, Hall IE, Schröppel B, Ficek J, Formica RN, Weng FL, Hasz RD, Thiessen-Philbrook H, Parikh C. Utility of Applying Quality Assessment Tools for Kidneys With KDPI ≥80. Transplantation 2017, 101: 1125-1133. PMID: 27490414, PMCID: PMC5290306, DOI: 10.1097/tp.0000000000001388.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkersBiopsyDecision Support TechniquesDonor SelectionFemaleGraft SurvivalHumansKaplan-Meier EstimateKidneyKidney TransplantationMaleMiddle AgedPredictive Value of TestsProcess Assessment, Health CareProspective StudiesQuality Indicators, Health CareRisk AssessmentRisk FactorsTissue DonorsTissue SurvivalTreatment OutcomeUnited StatesConceptsKidney Donor Profile IndexGroup 1High kidney donor profile indexDonor kidney poolViability of kidneysGlomerular filtration rateOutcomes of kidneysNumber of kidneysQuality assessment toolKidney poolViable kidneysBiopsy findingsGraft failureRenal resistanceDeceased donorsMulticenter studyFiltration rateBiomarker levelsGroup 3Kidney abnormalitiesKidneySignificant differencesHigh rateAssessment toolProfile indexOpportunities to Increase Availability of Deceased Donor Kidneys
Formica RN. Opportunities to Increase Availability of Deceased Donor Kidneys. Clinical Journal Of The American Society Of Nephrology 2017, 12: 871-873. PMID: 28546441, PMCID: PMC5460703, DOI: 10.2215/cjn.04490417.Peer-Reviewed Original ResearchIntegrating APOL1 Gene Variants Into Renal Transplantation: Considerations Arising From the American Society of Transplantation Expert Conference
Newell KA, Formica RN, Gill JS, Schold JD, Allan JS, Covington SH, Wiseman AC, Chandraker A. Integrating APOL1 Gene Variants Into Renal Transplantation: Considerations Arising From the American Society of Transplantation Expert Conference. American Journal Of Transplantation 2017, 17: 901-911. PMID: 27997071, DOI: 10.1111/ajt.14173.Peer-Reviewed Original ResearchMeSH KeywordsApolipoprotein L1Clinical Decision-MakingCongresses as TopicGenetic VariationHumansKidney Failure, ChronicKidney TransplantationPractice Patterns, Physicians'ConceptsEnd-stage renal diseaseAPOL1 risk allelesApolipoprotein 1Risk allelesKidney donationEvidence-based guidelinesClinical decision-making processAmerican SocietyAPOL1 gene variantsPercent of individualsKidney transplantationRenal transplantationRenal diseaseCase reportGeneral populationClinical practiceTransplantationAPOL1 variantsGene variantsKidneyAfrican ancestryCurrent dataExpert conferenceLimited studiesReport